Treatment references

Part 1

AbbVie, 2017 [press release]. Risankizumab Meets All Primary Endpoints Reporting Positive Results in Fourth Pivotal Phase 3 Psoriasis Study. Available at https://news.abbvie.com/news/risankizumab-meets-all-primary-endpoints-reporting-positive-results-in-fourth-pivotal-phase-3-psoriasis-study.htm (accessed September 2019).

Abbvie, 2019a [press release]. European Commission Approves SKYRIZI™ (risankizumab) for the Treatment of Moderate to Severe Plaque Psoriasis. Available at https://news.abbvie.com/news/press-releases/european-commission-approves-skyrizi-risankizumab-for-treatment-moderate-to-severe-plaque-psoriasis.htm (accessed November 2019).

Abbvie, 2019b [press release]. AbbVie expands immunology portfolio in the U.S. with FDA approval of SKYRIZI (risankizumab-rzaa) for moderate to severe plaque psoriasis. April 2019. Available at https://news.abbvie.com/news/press-releases/abbvie-expands-immunology-portfolio-in-us-with-fda-approval-skyrizi-risankizumab-rzaa-for-moderate-to-severe-plaque-psoriasis.htm (accessed September 2019).

AbuHilal M, Walsh S, Shear N. Use of Apremilast in Combination With Other Therapies for Treatment of Chronic Plaque Psoriasis: A Retrospective Study. J Cutan Med Surg. 2016;20:313–6.

Aldredge LM, Young MS. Providing guidance for patients with moderate-to-severe psoriasis who are candidates for biological therapy. J Dermatol Nurses Assoc. 2016;8:14–26.

Almutawa F, Alnomair N, Wang Y, Hamzavi I, Lim HW. Systematic review of UV-based therapy for psoriasis. Am J Clin Dermatol. 2013;14(2):87–109.

Armstrong AW, Betts KA, Sundaram M, Thomason D, Signorovitch JE. Comparative efficacy and incremental cost per responder of methotrexate versus apremilast for methotrexate-naïve patients with psoriasis. J Am Acad Dermatol. 2016;75(4):740–6.

Armstrong AW, Lynde CW, McBride SR, Ståhle M, Edson-Heredia E, Zhu B, et al. Effect of Ixekizumab Treatment on Work Productivity for Patients With Moderate-to-Severe Plaque Psoriasis: Analysis of Results From 3 Randomized Phase 3 Clinical Trials. JAMA Dermatol. 2016;152:661–9.

Armstrong AW, Siegel MP, Bagel J, Boh EE, Buell M, Cooper KD, et al. From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis. J Am Acad Dermatol. 2017;76(2):290–298.

Armstrong A, Agada N, Xu W, Gallo G. An update on the long-term safety experience of ixekizumab: results from the psoriasis clinical development programme with more than 3 years of follow-up from 12 clinical trials and more than 15000 patient-years of exposure. Presented at the 27th European Academy of Dermatology and Venerology Congress, 12–16 September 2018. Paris, France. P1825.

Arnold T, Schaarschmidt ML , Herr R , Fischer JE, Goerdt S, Peitsch WK. Drug survival rates and reasons for drug discontinuation in psoriasis. J Dtsch Dermatol Ges. 2016;14:1089–1099.

Atalay S, van den Reek J, van Vugt L, Kooijmans-Otero M, Davy Njoo M, Martinus Mommers J, et al. Results of the first randomised controlled trial on tight controlled dose resuction of biologicals compared with usual care in psoriasis patients: the CONDOR study. Presented at the European Academy of Dermatology and Venereology Congress 2018, 12–16 September 2018. Paris, France. D3T01.1K.

Augustin M, Abeysinghe S, Mallya U, Qureshi A, Roskell N, McBride D, et al. Secukinumab treatment of plaque psoriasis shows early improvement in DLQI response - results of a phase II regimen-finding trial. J Eur Acad Dermatol Venereol. 2016;30:645–9.

Augustin M, Blome C, Paul C, Puig L, Luger T, Lambert J, et al. Quality of life and patient benefit following transition from methotrexate to ustekinumab in psoriasis. J Eur Acad Dermatol Venereol. 2017;31(2):294–303.

Augustin M, Weglowska J, Lebwohl M, Paul C, Piguet V, Sofen H, et al. Durability of response in patients with chronic plaque psoriasis treated with certolizumab pegol over 48 weeks: pooled results from ongoing phase 3, multicentre, randomised, placebo-controlled studies (CIMPASI-1, CIMPASI-2 and CIMPACT). Presented at 27th European Academy of Dermatology and Venerology Congress, 12–16 September 2018. Paris, France. P1882.

Bachelez H, van de Kerkhof PC, Strohal R, Kubanov A, Valenzuela F, Lee JH, et al. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. Lancet. 2015;386:552–61.

Bachelez H, Chih-Ho Hong H, Pinter A, Elewski BE, Rich PA, Gu Y, et al. Efficacy and safety of risankizumab compared with placebo in patients with moderate-to-severe plaque psoriasis: integrated analyses from three phase 3 trials. Presented at 27th European Academy of Dermatology and Venerology Congress, 12–16 September 2018. Paris, France. P1865.

Bagel J, Nia J, Hashim PW, Patekar M, de Vera A, Hugot S, et al. Secukinumab is Superior to Ustekinumab in Clearing Skin of Patients with Moderate to Severe Plaque Psoriasis (16-week CLARITY Results). Dermatol Ther (Heidelb). 2018;8(4):571–579.

Bagel J, Nia J, Hashim PW, Patekar M, Hugot S, Sheng K et al. Secukinumab is superior to ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: CLARITY, a randomized, controlled, phase 3b trial. 2019 AAD Annual Meeting, Washington DC, 01–05 March 2019. Poster 8681. Available at: https://www.aad.org/eposters/Submissions/getFile.aspx?id=8681&type=sub (accessed March 2019).

Belge K, Brück J, Ghoreschi K. Advances in treating psoriasis. F1000Prime Rep. 2014;6:4.

Belinchón I , Rivera R , Blanch C , Comellas M , Lizán L . Adherence, satisfaction and preferences for treatment in patients with psoriasis in the European Union: a systematic review of the literature. Patient Prefer Adherence. 2016;10:2357–2367.

Beroukhim K, Danesh M, Nguyen C, Farahnik B, Levin E, Leon A, Koo J. A prospective, interventional assessment of the impact of ustekinumab treatment on psoriasis-related work productivity and activity impairment. J Dermatolog Treat. 2016;27:552–5.

BioSpace, 2019. LEO Pharma Inc. Announces U.S. Food and Drug Administration (FDA) expanded regulatory approvals for Enstilar® Foam and Taclonex® topical suspension in treatment of plaque psoriasis [press release]. Available at https://www.biospace.com/article/releases/leo-pharma-inc-announces-u-s-food-and-drug-administration-fda-expanded-regulatory-approvals-for-enstilar-foam-and-taclonex-topical-suspension-in-treatment-of-plaque-psoriasis/ (accessed September 2019).

Bissonnette R, Pariser DM, Wasel NR, Goncalves J, Day RM, Chen A, Sebastian M. Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis. J Am Acad Dermatol. 2016:75;99–105.

Bissonnette R, Luger T, Thaçi D, Toth D, Lacombe A, Xia S, Mazur R, Patekar M, Charef P, Milutinovic M, Leonardi C, Mrowietz U. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE extension study). J Eur Acad Dermatol Venerol. 2018b;32(9):1507‒14.

Blauvelt A, Prinz JC, Gottlieb AB, Kingo K, Sofen H, Ruer-Mulard M, et al. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). Br J Dermatol. 2015a;172(2):484–93.

Blauvelt A, Korman N, Mollon P, Zhao Y, Milutinovic MYou R, et al. Secukinumab treatment provides faster and more effective relief from patient reported quality of life impact than ustekinumab in subjects with moderate to severe psoriasis. EADV. Copenhagen, Denmark. 7–11 October, 2015b. P1698.

Blauvelt D, Sigurgeirsson B, Langley R, Tyring S, Messina I, Loeffler J, et al. Secukinumab treatment maintains efficacy in moderate to severe plaque psoriasis through second year of treatment: A randomized extension of the ERASURE and FIXTURE studies. American Academy of Dermatology. 73rd Annual Meeting, San Francisco, California. Late-Breaking Research Abstract Forums, Abstract Book. March 20–24, 2015c.

Blauvelt A, Cohen AD, Puig L, Vender R, van der Walt J, Wu JJ. Biosimilars for Psoriasis: Pre-Clinical Analytical Assessment to Determine Similarity. Br J Dermatol. 2016a;174:282–6.

Blauvelt A, Papp KA, Griffiths CE, Randazzo B, Wasfi Y, Shen YK, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017a;76:405–17.

Blauvelt A, Reich K, Tsai TF, Tyring S, Vanaclocha F, Kingo K, Ziv M, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study. J Am Acad Dermatol. 2017b;76:60–69.e9.

Blauvelt A, Gooderham M, Iversen L, Ball S, Zhang L, Agada NO, et al. Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3). J Am Acad Dermatol. 2017c;77(5):855–862.

Blauvelt A, Papp KA, Gooderham M, et al. Efficacy and Safety of Risankizumab, an IL-23 Inhibitor, in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: 16-Week Results from the Phase 3 IMMhance Trial; Poster presented at: 14th Annual Maui Derm for Dermatologists Conference; January 28 to February 1 2018; Maui.

Blauvelt A, Sofen H, Papp K, Gooderham M, Tyring S, Zhao Y, et al. Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate-to-severe psoriasis: A pooled analysis of two randomized controlled trials. J Eur Acad Dermatol Venereol. 2019 Aug 13 [Epub ahead of print].

Blome C, Gosau R, Radtke MA, Reich K, Rustenbach SJ, Spehr C, et al. Patient-relevant treatment goals in psoriasis. Arch Dermatol Res. 2016;308:69–78.

Boehncke WH, Boehncke S, Schön MP. Managing comorbid disease in patients with psoriasis. BMJ. 2010;340:b5666.

Boehncke WH, Boehncke S. More than skin-deep: the many dimensions of psoriatic disease. Swiss Med Wkly. 2014;144:w13968.

Boehncke WH, Schön MP. Psoriasis. Lancet. 2015;pii: S0140-6736(14)61909–7.

Bovenschen HJ, Langewouters AMG, van de Kerkhof PCM. Dimethylfumarate for psoriasis: Pronounced effects on lesional T-cell subsets, epidermal proliferation and differentiation, but not on natural killer T cells in immunohistochemical study. Am J Clin Dermatol 2010;11:343–50.

British National Formulary (BNF) 69. Published jointly by BMJ Publishing Group Ltd and Royal Pharmaceutical Society. ISBN: 978-0-85711-156-2. March 2015 – September 2015. P. 1–1164.

Callis Duffin K, Bagel J, Bukhalo M, Mercado Clement IJ, Choi SL, Zhao F, et al. Phase 3, open-label, randomized study of the pharmacokinetics, efficacy and safety of ixekizumab following subcutaneous administration using a prefilled syringe or an autoinjector in patients with moderate-to-severe plaque psoriasis (UNCOVER-A). J Eur Acad Dermatol Venereol. 2017;31(1):107–113.

Cavalla D. Off-label Prescribing: Justifying unapproved medicine. Chichester, UK: John Wiley & Sons, Ltd. 2015.

Chan TC, Hawkes JE, Krueger JG. Interleukin 23 in the skin: role in psoriasis pathogenesis and selective interleukin 23 blockade as treatment. Ther Adv Chronic Dis. 2018;9(5):111–9.

Chandrakumar SF, Yeung J. Interleukin-17 antagonists in the treatment of psoriasis. J Cutan Med Surg. 2014;18:223–8.

Chiricozzi A, Panduri S, Dini V, Tonini A, Gualtieri B, Romanelli M. Optimizing acitretin use in patients with plaque psoriasis. Dermatol Ther. 2017;30(2).

Cimzia, Summary of Product Characteristics, 2018 . Available at https://www.medicines.org.uk/emc/product/4450/smpc (accessed September 2019).

Certolizumab, ClinicalTrials.gov. Available at https://clinicaltrials.gov/ct2/results?term=certolizumab&cond=psoriasis (accessed September 2019).

Cohen SN, Baron SE, Archer CB. Guidance on the diagnosis and clinical management of psoriasis. Clin Experiment Dermatol. 2012;37(Suppl 1):13–8.

Colombo D, Di Pietro A. Systemic Cyclosporin in the Treatment of Psoriasis, Psoriasis, Dr. Jennifer Soung (Ed.), ISBN: 978-953-307-878-6, InTech, 2012. Available at:  https://www.intechopen.com/books/psoriasis/systemic-cyclosporine-in-the-treatment-of-psoriasis-and-psoriaticarthritis (accessed September 2019).

Cosentyx, Summary of Product Characteristics, 2015. Available at https://www.medicines.org.uk/emc/medicine/29848 (accessed September 2019).

Crowley J, Skup M, Thompson E, Yang M, Wu EQ, Huang X, et al. Patient-reported outcomes from the IMMVENT trial: comparison of risankizumab with adalimumab in moderate to severe psoriasis patients. Presented at 27th European Academy of Dermatology and Venerology Congress, 12–16 September 2018. P1947.

Crowley JJ, Warren RB, Cather JC. Safety of selective IL-23p19 inhibitors for the treatment of psoriasis. J Eur Acad Dermatol Venereol. 2019;33:1676–1684.

De Simone C, Caldarola G, Maiorino A, Tassone F, Campana I, Sollena P, Peris K. Clinical predictors of nonresponse to anti-TNF-α agents in psoriatic patients: A retrospective study. Dermatol Ther. 2016;29:372–376.

De Vries AC, Thio HB, de Kort WJ, Opmeer BC, van der Stok HM, de Jong EM, et al. A prospective randomised controlled trial comparing infliximab and etanercept in patients with moderate to severe chronic plaque type psoriasis Psoriasis Infliximab versus Etanercept Comparison Evaluation, the PIECE study. Br J Dermatol. 2017;176:624-33.

Dermatology News, 2019. CONDOR trial: Most psoriasis patients can be downshifted to reduced-dose biologics. Available at: https://www.mdedge.com/edermatologynews/article/191901/psoriasis/condor-trial-most-psoriasis-patients-can-be-downshifted. (Accessed January 2019).

Dogra S, Yadav S. Acitretin in psoriasis: an evolving scenario. Int J Dermatol. 2014;53(5):525–38.

Dommasch ED, Abuabara K, Shin DB, Nguyen J, Troxel AB, Gelfand JM. The risk of infection and malignancy with tumour necrosis factor antagonists in adult patients with psoriatic diseases: A systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol. 2011;64:1035–50.

Dommasch ED, Kim SC, Lee MP, Gagne JJ. Risk of Serious Infection in Patients Receiving Systemic Medications for the Treatment of Psoriasis. JAMA Dermatol. 2019;155(7):865.

Ehst, B. “Real world” use of ustekinumab for psoriasis, including palmar-plantar disease, and psoriatic arthritis: A comprehensive, retrospective chart review of an academic outpatient clinic. 23rd World Congress of Dermatology. Vancouver, Canada. June 8–13, 2015. Abstract 3087414.

European Medicines Agency (EMA), 2019. New measures to avoid potentially fatal dosing errors with methotrexate for inflammatory diseases [press release]. Available at https://www.ema.europa.eu/en/news/new-measures-avoid-potentially-fatal-dosing-errors-methotrexate-inflammatory-diseases (accessed September 2019).

Enbrel, Summary of Product Characteristics, 2015. Available at https://www.medicines.org.uk/emc/product/273/smpc (accessed September 2019).

European Medicines Agency (EMA), 2014. Biosimilar medicines. Available at  http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/general/general_content_001832.jsp&mid=WC0b01ac0580bb8fda (accessed September 2019).

European Medicines Agency (EMA). Assessment report: Remsima. 27 June 2013.. Available at  http://www.ema.europa.eu/docs/en_GB/document_library/EPAR__Public_assessment_report/human/002576/WC500151486.pdf.(accessed September 2019).

European Medicines Agency (EMA). Cosentyx. March 2015. Available at http://www.ema.europa.eu/ema/index.jspcurl=pages/medicines/human/medicines/003729/human_med_001832.jsp&mid=WC0b01ac058001d124 (accessed September 2019).

European Medicines Agency (EMA). Kyntheum. July 2017. Available at http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003959/human_med_002054.jsp&mid=WC0b01ac058001d124 (accessed September 2019).

European Medicines Agency (EMA). Skilarence. June 2017. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/skilarence#assessment-history-section (accessed September 2019).

European Medicines Agency (EMA). Summary of opinion (initial authorisation), Otezla (apremilast). November 2014 [cited 14 December 2015]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/003746/WC500177621.pdf.

European Medicines Agency (EMA). Summary of opinion (initial authorisation): Ixekizumab. 25 February 2016 [cited 26 April 2016]. Available http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/003943/WC500202360.pdf (accessed September 2019).

European Medicines Agency (EMA). Tremfya. November 2017. Available at http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004271/human_med_002183.jsp&mid=WC0b01ac058001d124 (accessed September 2019).

Eyerich K, von Kiedrowski R, Termeer C, Pinter A, Wegner S, Rausch C, et al. The safety profile of guselkumab is favorable compared to fumaric acid esters in psoriasis patients who are candidates for and naive to systemic treatment - safety results from the Germany-wide POLARIS trial. Presented at 27th European Academy of Dermatology and Venerology Congress, 12–16 September 2018. P1808.

FDA Drug Safety Communication: FDA warns about case of rare brain infection PML with MS drug Tecfidera (dimethyl fumarate) [safety announcement]. Available at http://www.fda.gov/Drugs/DrugSafety/ucm424625.htm (accessed September 2019).

Feldman SR. Inflammatory diseases: Integrating biosimilars into clinical practice. Semin Arthritis Rheum. 2015b ;44(6 Suppl):S16–21.

Feldman SR, Thaçi D, Gooderham M, Augustin M, de la Cruz C, Mallbris L, et al. Tofacitinib improves pruritus and health-related quality of life up to 52 weeks: Results from 2 randomized phase III trials in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2016;75(6):1162–1170.e3.

Feldman SR, Gomez B, Meng X, Germino R. Secukinumab rapidly improves mobility, self-care, and usual activities in patients with psoriasis: pooled analysis from four Phase 3 trials. Presented at Maui Derm for Dermatologists Congress 2019, 26–30 January 2019. Maui, Hawaii, USA.

Ferris LK, Ott E, Jiang J, Hong HC, Li S, Han C, Baran W. Efficacy and safety of guselkumab, administered with a novel patient-controlled injector (One-Press), for moderate-to-severe psoriasis: results from the phase 3 ORION study. J Dermatolog Treat. 2019;19:1-8.

Formycon, 2019 [press release]. Formycon announces news on development portfolio. Available at https://www.formycon.com/en/press-release/formycon-announces-news-on-development-portfolio/ (accessed September 2019).

Fotiadou C, Lazaridou E, Sotiriou E, Ioannides D. Targeting IL-23 in psoriasis: current perspectives. Psoriasis (Auckl). 2018;8:1–5.

Foulkes AC, Warren RB. Brodalumab in psoriasis: evidence to date and clinical potential. Drugs Context. 2019; 8: 212570.

Fragoulis GE, McInnes IB, Siebert S. JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis. Rheumatology 2019;58:i43–54.

GaBI online, 2018. EMA approval for infliximab biosimilar Zessly. Available at http://www.gabionline.net/Biosimilars/News/EMA-approval-for-infliximab-biosimilar-Zessly (accessed September 2019).

Galluzzo M, D'Adamio S, Silvaggio D, Lombardo P, Massaro A, Egan CG et al. Ustekinumab treatment for moderate-to-severe plaque psoriasis: eight-year real-life experience. Expert Opin Biol Ther. 2019;30:1–10.

Ghoreschi K, Brück J, Kellerer C, Deng C, Peng H, Rothfuss O, et al. Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells. J Exp Med 2011a;208:2291–303.

Ghoreschi K, Jesson MI, Li X, Lee JL, Ghosh S, Alsup JW, et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol 2011b;186:4234–43.

Gisondi P, Geat D, Pizzolato M, Girolomoni G. State of the art and pharmacological pipeline of biologics for chronic plaque psoriasis. Curr Opin Pharmacol. 2019;46:90–99.

Gordon KB, Blauvelt A, Papp KA, Langley RG, Luger T, Ohtsuki M, et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375(4):345–56.

Gordon KB, Han C, Li S, You Y, Song M, Fakharzadeh S, et al. Clinician-reported PASI response versus patient-reported symptoms and signs among patients with moderate to severe psoriasis: results from the VOYAGE 1 & 2 clinical trials. Presented at 27th European Academy of Dermatology and Venerology Congress, 12–16 September 2018a. P2035.

Gordon KB, Strober K, Lebwohl B, Augustin M, Blauvelt M, Poulin A, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. The Lancet. 2018b;392:650–661.

Gossec L, Smolen J, Gaujoux-Viala C, Ash Z, Marzo-Ortega H, van der Heijde D, et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis 2012;71:4–12.

Gottlieb AB, Kalb RE, Langley RG, Krueger GG, de Jong EM, Guenther L, et al. Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapies. J Drugs Dermatol. 2014;13:1441–8.

Gottlieb AB, Langley RG, Philipp S, Sigurgeirsson B, Blauvelt A, Martin R, et al. Secukinumab improves physical function in subjects with plaque psoriasis and psoriatic arthritis: Results from two randomized, Phase 3 trials. J Drugs Dermatol. 2015;14:821–33.

Gottlieb A, Sullivan J, van Doorn M, Kubanov A, You R, Parneix A, et al. Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial. J Am Acad Dermatol. 2017;76(1):70–80.

Gottlieb AB, Blauvelt A, Thaçi D, Leonardi CL, Poulin Y, Drew J, et al. Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2). J Am Acad Dermatol. 2018;79(2):302–14.e6.

Griffiths CE, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, et al; UNCOVER-2; UNCOVER-3 investigators. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386:541–51.

Griffiths CEM, Papp KA, Kimball AB, Randazzo B, Song M, Li S, et al. Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years. J Drugs Dermatol. 2018b;17(8):826­832.

Griffiths CEM, Thaci D, Iversen L, Peserico A, Pau-Charles I, Blauvelt A, et al. Tildrakizumab results in significant and sustained improvements in health-related quality of life in patients with moderate-to-severe psoriasis in a phase 3 trial (reSURFACE1). Presented at 27th European Academy of Dermatology and Venerology Congress, 12–16 September 2018c. P1922.

Grine L, Dejager L, Libert C, Vandenbroucke RE. An inflammatory triangle in psoriasis: TNF, type 1 IFNs and IL-17.Cytokine Growth Factor Rev. 2015;26:25–33.

Guenther L, Han C, Rubel D, Li S, You Y, Song M, et al.  Patient-reported outcomes in adalimumab inadequate responders after switch to guselkumab: results from clinical trial VOYAGE 2. Presented at 27th European Academy of Dermatology and Venerology Congress, 12–16 September 2018. P1926.

Guinard E, Bulai Livideanu C, Barthélémy H, Viguier M, Reguiai Z, Richard MA, et al. Active tuberculosis in psoriasis patients treated with TNF antagonists: a French nationwide retrospective study. J Eur Acad Dermatol Venereol. 2016;30:1336–41.

Gyulai R, Bagot M, Griffiths CE, Luger T, Naldi L, Paul C et al. Current practice of methotrexate use for psoriasis: results of a worldwide survey among dermatologists. J Eur Acad Dermatol Venereol. 2015;29(2):224–31.

Gyulai R, Bagot M, Griffiths CE, Luger T, Naldi L, Paul C, Puig L, Kemény L; Psoriasis International Network. Current practice of methotrexate use for psoriasis: results of a worldwide survey among dermatologists. J Eur Acad Dermatol Venereol. 2015;29:224–31.

Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol. 2017;140(3):645–53.

Humira, Summary of Product Characteristics, 2003. Available at https://www.medicines.org.uk/emc/product/2150/smpc (accessed September 2019).

Ilumya, Prescribing Information. 2018. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761067s000lbl.pdf (accessed September 2019).

Janssen, 2018 [press release]. New Phase 3 data demonstrate superiority of TREMFYA® (guselkumab) vs Cosentyx® (secukinumab) in delivering PASI 90 responses in the treatment of moderate to severe plaque psoriasis at week 48. Available at  https://www.janssen.com/new-phase-3-data-demonstrate-superiority-tremfyar-guselkumab-vs-cosentyxr-secukinumab-delivering (accessed September 2019).

Janssen, 2019a [press release]. Janssen announces new three-year TREMFYA® (guselkumab) data demonstrates stably maintained rates of skin clearance in patients with moderate to severe plaque psoriasis. Available at: https://www.jnj.com/janssen-announces-new-three-year-tremfya-guselkumab-data-demonstrates-stably-maintained-rates-of-skin-clearance-in-patients-with-moderate-to-severe-plaque-psoriasis (accessed September 2019).

Jannsen, 2019b [press release]. Janssen announces U.S. FDA approval of novel TREMFYA® (guselkumab) one-press patient-controlled injector for adults with moderate-to-severe plaque psoriasis [press release]. Available at https://www.janssen.com/janssen-announces-us-fda-approval-novel-tremfyar-guselkumab-one-press-patient-controlled-injector (accessed September 2019).

Jha A, Upton A, Dunlop WC, Akehurst R. The Budget Impact of Biosimilar Infliximab (Remsima®) for the Treatment of Autoimmune Diseases in Five European Countries. Adv Ther. 2015;32:742–56.

Kalb RE, Fiorentino DF, Lebwohl MG, Toole J, Poulin Y, Cohen AD, et al. Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR). JAMA Dermatol. 2015;151:961–9.

Kim J, Krueger JG. Highly effective new treatments for psoriasis target the IL-23/type 17 T cell autoimmune axis. Annu Rev Med. 2017;68:255–69.

Kircik L, Fowler J, Weiss J, Meng X, Guana A, Nyirady J. Efficacy of secukinumab for moderate-to-severe head and neck psoriasis over 52 weeks: Pooled analysis of four phase 3 studies. Dermatol Ther (Heidelb). 2016;6:627–638.

Kyntheum, Summary of Product Characteristics, 2017. Available at https://www.medicines.org.uk/emc/product/751 (accessed September 2019).

Landells I, Marano C, Hsu MC, Li S, Zhu Y, Eichenfield LF, et al. Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: Results of the randomized phase 3 CADMUS study. J Am Acad Dermatol. 2015 ; 73:594–603.

Login/ Register Maximise Minimise